"DIC"@en . . . "HSDB 3219"@en . "For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents."@en . "5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide"@en . . "Less than 5%"@en . "investigational"@en . . "4-(Dimethyltriazeno)imidazole-5-carboxamide"@en . "5 hours"@en . "5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide"@en . "Humans and other mammals"@en . . "4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide"@en . . . . . "Dacarbazinum"@en . . . . "An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma."@en . . . . "5-(Dimethyltriazeno)imidazole-4-carboxamide"@en . "The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific."@en . " "@en . . . . "Dacarbazine"@en . "DTIE"@en . . . . "ICDMT"@en . . "4342-03-4"@en . . "Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-"@en . . "LD₅₀=350mg/kg (orally in mice)"@en . "NCI-C04717"@en . . . . . . . "4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide"@en . "Dacarbazine"@en . . . "Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine."@en . . . "DTCI"@en . . . . . . . . . . . . . . . . . . . . . . "Dacarbazina"@en . "Imidazole Carboxamide"@en . . "NSC-45388"@en . . . "Erratic, slow and incomplete"@en . . "Biocarbazine"@en . . "Dacarbazin"@en . "Dtic-dome (tn)"@en . "approved"@en . "NSC 45388"@en .